Why the study?
Heart failure carries a considerable burden of disability often related to co-existing co-morbidities, driving an emphasis on treating common co-morbidities that until recently received little attention.
Answers are grounded in this paper and cite their sources.
This review emphasizes the therapeutic potential of targeting specific comorbidities in heart failure, particularly highlighting the robust benefits of SGLT2 inhibitors and the nuanced role of percutaneous mitral valve repair.
Heart failure (HF) is a condition that carries a considerable burden of disability many now related to co-existing co-morbidities. The drive to find newer effective therapies targeting novel mechanisms has led to a recent emphasis on treating common co-morbidities that are clustered around contemporary HF patients. Here is renewed contemporary co-morbidities that until recently have received little attention but which are now subject of considerable interest and potential therapeutic advance. These include, diabetes, functional mitral regurgitation and sleep disordered breathing. These three contemporary co-morbidities that have recently been subject to major trial evaluation will be reviewed in this paper.
No takes yet. Share an insight, caveat, or question.
Andrew J.S. Coats (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: